Influenza Vaccine Post Allogeneic Transplant
Influenza Vaccine Post Allogeneic Transplant
Study Design:

 This is a randomized, single center study to evaluate immune responses to the seasonal
 influenza vaccine in allogeneic hematopoietic stem cell transplant (HSCT) recipients who
 receive one vaccine or two vaccine doses one month apart. In addition, a cohort of healthy
 adult volunteers will be recruited as controls to confirm immune response to a single
 influenza vaccine.
Inclusion Criteria:

 -  Patient Population

 -  HSCT recipients who are greater than 60 days post transplant.

 -  Age 6 months and older who are greater than 60 days post post allogeneic
 hematopoietic cell transplant

 -  Show neutrophil recovery, platelet count > 50,000/mm3 (may be transfused), no
 known disease relapse

 -  No history of previous allergic reaction to influenza vaccine, known egg allergy
 or Guillan-Barre Syndrome

 -  No flu vaccine in previous 4 months, no Campath in previous 6 months, no
 intravenous immune globulin (IVIG) in previous 3 months

 -  Controls:

 -  Age 18 to 50 years

 -  No history of previous allergic reaction to influenza vaccine, known egg allergy
 or Guillan-Barre Syndrome

 -  No flu vaccine in previous 4 months